Measuring Oncological Value of Exercise and Statin (MOVES)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05796973 |
Recruitment Status :
Recruiting
First Posted : April 4, 2023
Last Update Posted : May 16, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer Breast Cancer Kidney Cancer Ovarian Cancer Metastatic Breast Cancer Metastatic Kidney Cancer Metastatic Renal Cell Carcinoma Metastatic Renal Cancer Metastatic Prostate Cancer Metastatic Prostate Adenocarcinoma Metastatic Ovarian Cancer Metastatic Ovary Cancer | Behavioral: Guided physical exercise Drug: Atorvastatin Other: Independent exercise | Phase 3 |
![Show](/ct2/html/images/expand.png)
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 240 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The patients are randomized equally into three groups: 1/3 into guided exercise group, 1/3 into guided exercise and statin-treatment group and 1/3 into non-guided exercise group |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin |
Actual Study Start Date : | March 31, 2023 |
Estimated Primary Completion Date : | December 31, 2025 |
Estimated Study Completion Date : | December 31, 2027 |
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Arm | Intervention/treatment |
---|---|
Experimental: Guided physical exercise arm
20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit. In addition, as a separate group, 20 patients from each type of cancer (altogether 80) who are already using statin medication are randomized to this arm. |
Behavioral: Guided physical exercise
Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. |
Experimental: Atorvastatin arm
20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise + atorvastatin (40 mg QD) arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit.
|
Behavioral: Guided physical exercise
Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. Drug: Atorvastatin Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication. |
Active Comparator: Non-guided physical exercise arm
20 patients from each type of cancer (altogether 80) are randomized to a non-guided physical exercise arm. The patients' physical condition and body composition are measured at baseline. The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own. The physical condition and body composition of this group is also measured at three months and six months after baseline to detect changes. After that the patients are given advise to exercise regularly and this is asked during each follow-up visit. In addition, as a separate group, 20 patients from each type of cancer (altogether 80) who are already using statin medication are randomized to this arm. |
Other: Independent exercise
The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own. |
- Time to cancer progression [ Time Frame: From randomization until the date of first documented progression, assessed at twelve week intervals up to 24 months ]
Radiological progression • Radiological progression of the disease according to RECIST criteria (version 1.1.) compared to the situation at the start of cancer treatment in all cancer types. If the cancer treatment includes the use of immune checkpoint inhibitors, the imRECIST criteria are applied to evaluate the response
In addition, the disease is considered advanced if both of the criteria below are met:
-
Biochemical progression:
- PSA progression in prostate cancer, (three consecutive PSA increases measured at least one week apart, two > 50% increases from the lowest PSA level and PSA > 2 ng/ml) with testosterone at castration level (< 50 ng/ml or 1.7 nmol/l)
- Ca15-3 marker increase in breast cancer (three consecutive marker increases that the clinician considers significant)
- In ovarian cancer, ca12-5 marker increase (three consecutive marker increases that the clinician considers significant)
- Clinical progression o ECOG 3 or less (long-term)
-
- Mortality [ Time Frame: From randomization until the date of death, assessed up to 24 months ]Time to death from the beginning of the first-line medication
- Hypoxia markers in serum (VEGF, HIF1-alpha, carboanhydrase IX, LADH) [ Time Frame: At baseline and at 3 months ]Hypoxia markers in the serum
- Tolerability of treatment [ Time Frame: From date of randomization, assessed at twelve week intervals up to 24 months ]Incidence of grade 3 or worse adverse events during cancer treatment
- Fat/muscle ratio as measured with impedance test [ Time Frame: At baseline and at 3 and 6 months ]Body composition measurement before and after the intervention
- Physical performance with standardized muscle strength tests [ Time Frame: At baseline and at 3 and 6 months ]Muscle strength tested with three standardized tests (squat test, core dynamic strength test, biceps flexion test) before and after the intervention.
- Changes in tissue hypoxia [ Time Frame: At baseline and at 3 months ]The amount of hypoxia in cancer foci determined by PET-CT scan using specific hypoxia-sensitive tracers in a sub-study
- Changes in quality of life [ Time Frame: At baseline and at 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months ]EORTC-QLQ-C30 questionnaire to measure quality of life, score from 0 to 100. A high scale score for a functional scale represents a higher level of functioning, a high score for a symptom scale represents higher level of symptoms.
- Depressive symptoms [ Time Frame: At baseline and at 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months ]Patient Health Questionnaire (PHQ-9), score from 0 (no depression) to 27 (severe depression).
- Severity of pain [ Time Frame: At baseline and at 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months ]The severity of pain and its impact on functioning. Brief Pain Inventory questionnaire including 9 items. Pain severity scale from 0 (no pain) to 10 (worst pain), pain interference from 0 (does not interfere) to 10 (completely interferes).
- Nutritional status [ Time Frame: At baseline and at 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months ]Mini Nutritional Assessment (MNA) questionnaire. A score of 7 or less (malnutrition) to 24-30 (normal nutrition).
- Relationship satisfaction [ Time Frame: At baseline and at three months, twelve months and 24 moths. ]The relationship questionnaire consists of two previously used, validated measures: Dyadic Adjustment Scale (DAS) and Marital Communication Inventory.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started
- Prostate cancer: First course of docetaxel treatment for metastatic prostate cancer.
- Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status.
- Kidney cancer: medium-risk/high-risk kidney cancer according to the IMDC classification, for which 1st-line cancer drug treatment is started as tki monotherapy or as a combination treatment that includes tki medication. - the randomization of subjects is stratified according to gender
- Ovarian cancer: stage III or IV cancer for which 1st-line chemotherapy treatment is started.
- The patient agrees to the study and signs a written informed consent.
- Adult (18 years=>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study.
- In women, the use of a reliable contraceptive during the intervention
Exclusion Criteria:
- High risk of bone fractures
- Inability to physical exertion and/or unsuitability for cancer drug treatment
- Poor co-operation ability for psychological reasons
- Active use of cholesterol-lowering drugs
- Severe liver or kidney failure
- Troublesome side effects that occurred in the past during cholesterol medication
- Continuous use of medicinal substances that interact with atorvastatin during the study period
- A special group of subjects according to the Medical Research Act (1999/488) (e.g. minors and pregnant or lactating women)
Exclusion criteria in patients who are already using statin medication before the study:
- High risk of bone fractures
- Inability to physical exertion and/or unsuitability for cancer drug treatment
- Poor co-operation ability for psychological reasons
- Severe liver or kidney failure
- A special group of subjects according to the Medical Research Act (1999/488) (e.g. minors and pregnant or lactating women)
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05796973
Contact: Teemu Murtola, MD PhD Prof | 03-311611 | teemu.murtola@tuni.fi | |
Contact: Jorma Sormunen, MD PhD MBA | 0505001869 | jorma.sormunen@fimnet.fi |
Finland | |
Tampere University Hospital | Recruiting |
Tampere, Länsi-Suomi, Finland, 33520 | |
Contact: Teemu Murtola, MD PhD Prof teemu.murtola@tuni.fi | |
Contact: Jorma Sormunen, MD PhD MBA jorma.sormunen@fimnet.fi |
Principal Investigator: | Teemu Murtola, MD PhD Prof | Tampere University Hospital |
Responsible Party: | Teemu Murtola, Professor of Urology, Chief Physician, Tampere University Hospital |
ClinicalTrials.gov Identifier: | NCT05796973 |
Other Study ID Numbers: |
2019-001982-34 |
First Posted: | April 4, 2023 Key Record Dates |
Last Update Posted: | May 16, 2024 |
Last Verified: | May 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Breast Neoplasms Prostatic Neoplasms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Carcinoma, Renal Cell Kidney Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Genital Diseases Urogenital Diseases |
Prostatic Diseases Male Urogenital Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Neoplasms, Female Endocrine System Diseases Gonadal Disorders |